Last reviewed · How we verify
low dose hCG
Low dose hCG, marketed by AZ Jan Palfijn Gent, is a currently available therapeutic with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | low dose hCG |
|---|---|
| Also known as | Pregnyl, Human chorionic gonadotrophin |
| Sponsor | AZ Jan Palfijn Gent |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm (PHASE2)
- Assessment of the Feasibility of Frozen Embryo Transfers in a Natural Cycle Among Obese Compared to Non-Obese Patients
- PET Image in PAH Patients (EARLY_PHASE1)
- Effects of Intrauterine Flushing With Human Chorionic Gonadotropin on ICSI Outcome (PHASE4)
- hCG Priming in Women With Diminished Ovarian Reserve (PHASE3)
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
- Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia (NA)
- Natural Versus Programmed Frozen Embryo Transfer (NatPro) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low dose hCG CI brief — competitive landscape report
- low dose hCG updates RSS · CI watch RSS
- AZ Jan Palfijn Gent portfolio CI